Skip to main content
Premium Trial:

Request an Annual Quote

AnaSpec, Bio-Rad Laboratories, Geneva Bioinformatics, Protein Discovery

Premium
AnaSpec last week released Fmoc-Ebes-OH, which the company said is an ideal spacer for peptide labeling in solid phase synthesis. The spacer has “better water solubility and ionization ability, making it more amenable for mass spectrometry analysis,” AnaSpec said in a statement.
 
The company also released 82 new antibodies targeting apoptosis, signal transduction, cancer research, and other applications. Included in the release are Anti-AIM/AP16, an apoptosis inhibitor of macrophages; Anti-Anthrax LF, an anthrax lethal factor; and AntiAPG7, an autophagy protein 7.
 

 
Bio-Rad Laboratories this week introduced its next generation Mini-Protean Tetra Cell 1-D electrophoresis gel system. The Mini-Protean uses two running modules and accommodates from one to four handcast or Ready Gel precast gels.
 

 
Geneva Bioinformatics launched PhenyxOnline this week. The online platform complements the existing PhenyxServer platform. Clients can now choose the software-as-a-service [SaaS] option, PhenyxOnline, or PhenyxServer that resides at the customer’s location. PhenyxOnline is the first commercial platform in the proteomics field offered in a SaaS model, the company said. Phenyx is a software platform for the identification and characterization of proteins and peptides from mass spectrometry data. It is designed specifically to “meet the concurrent demands of high-throughput MS data analysis and dynamic results assessment,” the company said in a statement.
 

 
Protein Discovery said this week PPS Silent Surfactant is now available in 1 milligram vials. The reagent, for use in preparing membrane proteins from small populations of microdissected cells prior to nanoLC/MS/MS analysis, is also available in 10 mg vials.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.